Neumora Therapeutics, Inc. (NMRA) Stock Statistics & Valuation Metrics

Neumora Therapeutics, Inc. has a market cap or net worth of $305.72M. The enterprise value is $136.82M.

Neumora Therapeutics, Inc. has 185,284,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Neumora Therapeutics, Inc.’s return on equity (ROE) is -2.28 and return on invested capital (ROIC) is -151.78%.

The current PE Ratio of Neumora Therapeutics, Inc. is ―. Neumora Therapeutics, Inc.’s PEG ratio is 0.24.

In the last 12 months, Neumora Therapeutics, Inc. had revenue of 0.00 and earned -236.93M in profits. Earnings per share was -1.45.

In the last 12 months, operating cash flow was -193.40M and capital expenditures 16.00K, giving a free cash flow of -193.40M billion.

Neumora Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Neumora Therapeutics, Inc. upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).

Neumora Therapeutics, Inc. as a current ratio of 5.87, with Debt / Equity ratio of 0.58%

In the past 12 months, Neumora Therapeutics, Inc. has paid 130.00K in taxes.

Neumora Therapeutics, Inc. EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.53.

Neumora Therapeutics, Inc. has $147.07M in cash and marketable securities with $410.00K in debt, giving a net cash position of $146.66M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Neumora Therapeutics, Inc. is $6.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy